 Home > Medical News > Latest Medical News > Eli Lilly’s application for new indications for IL-17A inhibitors is accepted by CDE

Eli Lilly’s application for new indications for IL-17A inhibitors is accepted by CDE

 Last Update: 2021-09-29
 Source: Internet
 Author: User

Tags

lidocaine show drug test

lyrica show drug test

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Text|Pharmaceutical Mission Hills

On September 23, the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China announced that Eli Lilly and Company had submitted a new indication marketing application for ixizumab injection and was accepted

Screenshot source: CDE official website

IL-17A is a naturally occurring cytokine involved in normal inflammation and immune response.

The ezizumab developed by Eli Lilly can selectively bind IL-17A and inhibit its interaction with IL-17 receptors

In the United States, ezizumab was first approved by the FDA in March 2016

In China, ezizumab was first approved in September 2019 for the treatment of adult patients with moderate to severe plaque psoriasis suitable for systemic therapy or phototherapy

Public information shows that in November 2019, ezizumab was approved in China for a clinical trial for radiologically positive axial spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic, autoinflammatory disease that mainly affects the axial bones, including radioactive axial spondylarthritis (r-axSpA) and non-radiology negative axial spondyloarthritis ( nr-axSpA) two kinds

Reference materials:

[1] Center for Drug Evaluation of China National Medical Products Administration.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.